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Abstract
Mammalian Target of Rapamycin Complex 1 (mTORC1) is activated by growth factor-regulated phosphoinositide 3-kinase
(PI3K)/Akt/Rheb signalling and extracellular amino acids (AAs) to promote growth and proliferation. These AAs induce
translocation of mTOR to late endosomes and lysosomes (LELs), subsequent activation via mechanisms involving the
presence of intralumenal AAs, and interaction between mTORC1 and a multiprotein assembly containing Rag GTPases and
the heterotrimeric Ragulator complex. However, the mechanisms by which AAs control these different aspects of mTORC1
activation are not well understood. We have recently shown that intracellular Proton-assisted Amino acid Transporter 1
(PAT1)/SLC36A1 is an essential mediator of AA-dependent mTORC1 activation. Here we demonstrate in Human Embryonic
Kidney (HEK-293) cells that PAT1 is primarily located on LELs, physically interacts with the Rag GTPases and is required for
normal AA-dependent mTOR relocalisation. We also use the powerful in vivo genetic methodologies available in Drosophila
to investigate the regulation of the PAT1/Rag/Ragulator complex. We show that GFP-tagged PATs reside at both the cell
surface and LELs in vivo, mirroring PAT1 distribution in several normal mammalian cell types. Elevated PI3K/Akt/Rheb
signalling increases intracellular levels of PATs and synergistically enhances PAT-induced growth via a mechanism requiring
endocytosis. In light of the recent identification of the vacuolar H
+-ATPase as another Rag-interacting component, we
propose a model in which PATs function as part of an AA-sensing engine that drives mTORC1 activation from LEL
compartments.
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Introduction
Mammalian Target of Rapamycin, (mTOR), is a critical
integrator of nutrient, energy and growth factor signals in higher
eukaryotes [1]. This kinase controls several key cell biological
processes, including protein translation, growth, the cell cycle and
autophagy. Defective mTOR signalling has been linked to a range
of major human diseases, including cancer [2], obesity [3], Type 2
diabetes [4,5] and several neurodegenerative disorders [6], as well
as having evolutionarily conserved effects on ageing [7,8].
Modulating mTOR activity could, therefore, have important
therapeutic implications for the treatment of human disease and
promoting healthy ageing. Indeed, strategies involving analogues
of the mTOR inhibitor rapamycin, so-called ‘rapalogs’, have been
approved by the FDA for the treatment of patients with advanced
renal carcinoma [9–11]. However, mTOR exists in at least two
characterised multicomponent complexes, mTORC1 and
mTORC2. Rapamycin and the rapalogs have been shown to
have the strongest effect on mTORC1, but there is some evidence
that they can also inhibit mTORC2 [12]. mTORC1 negatively
feeds back on Akt, a key target of growth factor signalling that
promotes mTORC1 activity. Furthermore, mTORC2 positively
regulates Akt [13]. There has therefore been recent interest in
developing drugs that target both mTORC1 and mTORC2, such
as the ATP-competitive mTOR kinase inhibitors [14,15]. How-
ever, the mTORC1 signalling pathway is globally active in all
cells, so directly targeting mTOR is likely to have significant
side effects. A preferable strategy might be to focus on any
nutrient-sensing mechanisms employed selectively by cancer cells
that allow them to compete successfully with their normal
neighbours [16].
The growth factor-regulated phosphoinositide 3-kinase (PI3K)/
Akt pathway is antagonised by the major human tumour
suppressor gene, PTEN, and is known to be hyperactivated in
the majority of human cancers [17,18]. Genetic analysis in flies has
been particularly helpful in establishing a link between PI3K/Akt
and the TORC1 signalling cascade via the G protein Rheb and its
antagonist, the Tuberous Sclerosis Complex (TSC; [19,20]). There
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cell culture [23] and mouse models [24] that in a nutrient- and
growth factor-depleted microenvironment, in which for example,
tumour cells often grow preferentially [25], increased PI3K/Akt
and mTORC1 signalling can give cells a major growth advantage.
Despite the central importance of mTORC1 in several basic
cellular functions, some aspects of its regulation are still poorly
characterised. For example, we do not understand the mechanism
by which extracellular amino acid (AA) levels are ‘sensed’ inside
cells and how they synergise with PI3K/Akt signalling to stimulate
mTORC1 [26,27]. In a recent breakthrough, the Rag GTPases
were shown to specifically modulate TORC1 signalling in cell
culture and in vivo, using genetic approaches in Drosophila [28,29].
They function as a heterodimeric complex between RagA or RagB
and RagC or RagD; which is involved in an AA-dependent
process that relocalises mTOR to late endosomes and lysosomes
(LELs; [29,30]), promoting assembly and activation of mTORC1.
This aspect of mTOR activation appears to be evolutionarily
ancient, because yeast TOR1 localises with the EGO complex,
which contains the yeast Rag GTPase orthologues, Gtr1p and
Gtr2p, and other regulatory components, such as the guanine
nucleotide exchange factor Vam6, near the vacuolar membrane, a
lysosome-like structure [31,32]. A trimeric complex of proteins,
dubbed the Ragulator, has been implicated in binding the Rag
GTPase heterodimer to the lipid bilayer [30].
However, the AA sensing mechanisms that drive the process of
mTOR relocalisation and activation remain unclear [33].
Membrane-associated molecules involved in this mechanism are
likely to be good therapeutic targets to combat tumour growth
[34], particularly if the regulatory mechanisms change as PI3K/
Akt signalling increases and cells become more resistant to
alterations in extracellular AA levels. Studies in cell culture have
highlighted several cell surface amino acid transporters (AATs),
including the solute carrier (SLC)1A5 glutamine transporter and
the heterodimeric CD98 (SLC7A5/SLC3A2) bidirectional AA
exchanger [35] that mediate the uptake of AAs. There are also a
number of intracellular signalling molecules other than the Rag
GTPases, e.g., MAP4K3 [36–38] and Vps34 [39,40], which are
thought to be involved in mediating the AA-dependent signal to
mTORC1 (reviewed in [26]), but there is no evidence that these
molecules act directly as AA sensors.
Other studies have shown that once the mTORC1/Rag/
Ragulator complex is assembled on LELs, a proton gradient across
the LEL membrane is required for mTORC1 to activate its
downstream targets [41]. During starvation, when cells enter
autophagy and recycle intracellular organelles and macromole-
cules to promote survival, mTORC1 is reactivated from auto-
lysosomal membranes in response to accumulation of intralumenal
AAs [42]. However, the AA sensing mechanism involved here has
also not been identified.
In a screen of different AATs for in vivo growth effects in
Drosophila, we found that a specific class of AAT, the Proton-
assisted (PAT or SLC36) Amino acid Transporters (reviewed in
[43–45]), has a particularly potent effect on TORC1-mediated
growth. The TORC1-regulatory role of the PATs is conserved in
humans [46]. Genetic and biochemical evidence suggests that in
response to AAs, the ubiquitously expressed human PATs, PAT1
and PAT4, promote phosphorylation of key downstream targets of
mTORC1 and are required for growth. Furthermore, in rapidly
growing cells, such as human embryonic kidney (HEK-293) and
MCF-7 breast cancer cells, PAT1 is localisation is intracellular
[46], suggesting that it is not involved in AA influx into the cell,
but in another downstream event in mTORC1 activation.
Here we show that in HEK-293 cells, PAT1 physically interacts
with Rag GTPases and co-localises with these molecules on LELs.
PAT1-positive LELs recruit mTOR upon exposure to AAs. We
also present evidence that PI3K/Akt/Rheb signalling promotes
PAT-dependent growth in flies via a mechanism that involves
endocytosis of cell surface PATs. Our data therefore suggest that
PATs and Rag GTPases complex at the surface of LELs to
promote activation of TORC1-mediated growth, and that growth
factor-mediated PI3K/Akt/Rheb signalling mediates some of its
effects on TORC1 by regulating the accumulation of this complex
inside normal cells. We propose a model to explain how the
interaction of AAs with PATs might be a critical part of the AA
sensing mechanism that drives TORC1 activation.
Results
mTOR is recruited to PAT1-containing late endosomes
and lysosomes upon AA stimulation
We have previously shown that the two ubiquitously expressed
PATs, PAT1 and PAT4, are critically required for activation of
mTORC1 by extracellular AAs in rapidly growing cultured cells,
even though PAT1 is predominantly located within cells [46]. To
determine the subcellular compartments in which PAT1 is
localised, we generated a stable HEK-293 cell line overexpressing
Flag-tagged PAT1, see supplemental methods (Methods S1).
Under steady state growth conditions, this fusion protein has a
punctate intracellular expression pattern, which is often primarily
localised in an asymmetric perinuclear cap (Figure 1B), and
resembles the expression of endogenous PAT1 (Figure 1A). Co-
labelling either non-transfected HEK-293 cells or Flag-PAT1-
expressing cells with an antibody against the LEL marker LAMP2
revealed extensive co-localisation in all cells (greater than 80% co-
localisation [n=20] for both Flag-PAT1 and endogenous PAT1).
These molecules co-localised both in AA-starved cells (Flag-PAT1
in Figure 1D) and after cells were first depleted of extracellular
AAs, then stimulated with AAs for 10 min (PAT1 in Figure 1C
and Flag-PAT1 in Figure 1E). We conclude that PAT1 is primarily
located in LEL compartments in HEK-293 cells and that this
distribution is not affected by the presence of extracellular AAs.
To determine whether PAT1-containing LEL compartments
recruit mTOR upon AA- stimulation, we co-immunostained the
Flag-PAT1 cell line with anti-mTOR and anti-LAMP2 antibodies;
although Flag-PAT1 and LAMP2 co-localise extensively in the
absence or presence of AAs (Figures 1D and 1E), mTOR shuttles
to a subset of the LAMP2/PAT1-positive compartments only in
the presence of AAs (Figure 1E). Consistent with previous studies
[29,30], mTOR is diffusely expressed throughout the cytoplasm in
starved cells and does not localise to LAMP2/PAT1-containing
compartments (Figure 1D). Immunogold-labelling and electron
microscopy of AA-replete cells, under steady state conditions,
revealed the presence of specific membrane-bound compartments.
These typically had electron-dense cores, containing both mTOR
and Flag-PAT1 (Figure 2). The immuno-positive mTOR mole-
cules were frequently sufficiently close (within 20 nm) to immuno-
positive PAT1 molecules to be part of a macromolecular complex.
This is consistent with the idea that PAT1 might be involved in the
recruitment of mTOR to these membranes or in the regulation of
mTOR at the membrane.
PAT1 and RagC form part of a putative amino acid-
sensing complex
In yeast, Gtr2p (the orthologue of both RagC and RagD),
regulates vesicular shuttling of an amino acid transporter (Gap1)
through a direct interaction with this molecule [47]. We found that
PAT1 Regulates TORC1 on LELs
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and AA-stimulated conditions (Figure 3B). Under AA-stimulated
conditions we observed less overlap between tagged PAT1 and
RagC than between PAT1 and LAMP2, suggesting that RagC
and PAT1 are co-located in only some LEL compartments. To
investigate whether RagC and PAT1 might physically interact,
Flag-PAT1 was immunoprecipitated with an anti-Flag antibody
from extracts of cells stably expressing the Flag-PAT1 construct.
Endogenous RagC was co-immunoprecipitated with Flag-PAT1
(Figure 3C), but was not precipitated from control cell lysates that
contained the empty pcDNA3.1 vector. Furthermore, Flag-
immunoprecipitated extracts from cells transiently expressing
Flag-RagD contained endogenous PAT1, but immunoprecipitated
extracts from cells transiently expressing another monomeric G
protein, Flag-Rap2A, did not (Figure 3D). We therefore conclude
that Rag GTPases not only co-localise with PAT1 in specific
LELs, but also form part of a multiprotein complex in these
compartments. Since PATs directly interact with AAs, and Rag
GTPases are also involved in AA-dependent processes that localise
and activate mTORC1, we reasoned that this complex might
participate in AA sensing.
To test this hypothesis, we investigated whether siRNA knock
down of PAT1, which we have previously shown severely inhibits
mTORC1 activation [46], affects the AA-dependent relocalisation
of mTOR in HEK-293 cells. The relocalisation of mTOR was
partially but not completely suppressed, under these conditions
(Figure 4), indicating that PAT1 is involved in this process.
Figure 1. mTOR localises to LAMP2/PAT1-positive compartments upon AA stimulation. (A, B) Flag-PAT1 (red; B) overexpressed in a stably
transfected HEK-293 cell line has a similar intracellular localisation pattern to endogenous PAT1 (green; A). Cells under steady state conditions are
shown. (C) Endogenous PAT1 strongly co-localises with LAMP2, which marks LEL compartments. Cells were stained after 50 min AA starvation
followed by 10 min AA stimulation. Merge shows LAMP2 (red), PAT1 (green) and DAPI (blue). (D, E) Subcellular localisation of LAMP2, Flag-PAT1 and
mTOR after 50 min AA starvation (D) and 50 min AA starvation followed by 10 min AA stimulation (E). Note that Flag-PAT1 and LAMP2 co-localise
under both conditions, but mTOR is only recruited to a limited number of LELs upon AA stimulation. Merge shows Flag-PAT1 (red), mTOR (green) and
DAPI (blue). Scale bars in B and E are 10 mm, A; scale bar in B also applies to A and C, scale bar in E also applies to D.
doi:10.1371/journal.pone.0036616.g001
Figure 2. Flag-PAT1 and mTOR co-localise at the surface of the
same intracellular compartments. (A) Ultrathin sections from a
stable HEK-293 cell line overexpressing Flag-PAT1 and either labelled
with anti-Flag antibodies (5 nm gold) or (B–D) co-labelled with anti-
Flag (5 nm gold) and anti-mTOR (10 nm gold) antibodies. Endogenous
mTOR and Flag-PAT1 are found on the surface of the same membrane-
bound compartments that often contain an electron-dense core.
Arrowheads mark a subset of locations where immunolabelled mTOR
is in close enough proximity to Flag-PAT1 to be part of a multimolecular
complex. Scale bar is 200 nm in all panels.
doi:10.1371/journal.pone.0036616.g002
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Drosophila
Our analysis in immortalised cells in culture suggests that PAT1
is almost exclusively located on intracellular LELs from where it
promotes mTORC1-mediated growth. However, earlier studies in
normal mammalian cells in vivo suggest that, PATs are distributed
between the plasma membrane and intracellular compartments
[43,48] raising the possibility that differential distribution between
the cell surface and LELs is involved in regulating PAT activity.
We investigated this question in Drosophila, where the candidate
molecules that control PAT localisation can be more easily
genetically modulated in vivo. We have previously shown that
human PATs are able to promote growth and TORC1 activation
in flies [46], suggesting that PAT-dependent regulatory mecha-
nisms are likely to be highly conserved.
To assess the subcellular localisation of PAT transporters in
flies, we generated transgenic flies (Methods S1), expressing tagged
constructs in which Enhanced Green Fluorescent Protein (GFP) is
fused to the C-terminus of the coding sequences of two different
PATs (Methods S1) that have previously been shown to have
growth-promoting properties, PATH and CG1139 [49]. These
constructs, CG1139-GFP and Path-GFP, were expressed in
Drosophila, in a tissue- and stage-specific fashion, using the
GAL4/UAS targeted misexpression system [50]. Analysis of the
growth-promoting activity and subcellular localisation of both
tagged PATs produced similar results. We primarily present the
data for CG1139-GFP below.
We first tested for functional activity of tagged CG1139.
Previous studies have shown that low level, ubiquitous expression
of CG1139 can rescue the infertility and partially rescue the
reduced growth of a recessive path
KG06640 mutant [49]. Expression
of CG1139-GFP using the arm-GAL4 transgene employed in this
previous study, which drives low level ubiquitous expression,
resulted in a significant increase in the weight of recessive
path
KG06640 mutant flies from 0.8560.02 mg/female fly to
1.0260.05 mg/fly (P,0.01; normal control females weigh
1.1060.09 mg/fly), but like untagged CG1139 [49], had no
significant effect on wild type flies. Furthermore, mutant females,
which are normally infertile, produced offspring in the presence of
the tagged PAT. We therefore conclude that CG1139-GFP retains
normal in vivo functional activity.
Using multiple insertion lines, overexpression of the UAS-
CG1139-GFP and UAS-path-GFP constructs in the differentiating
eye with GMR-GAL4 generally produced a significant, but more
modest, increase in ommatidial size (Figures 5D, E) than UAS-
Figure 3. PAT1 co-localises and can physically interact with Rag GTPases. (A, B) Flag-PAT1 co-localises with a subset of the compartments
containing endogenous RagC under both AA-starved (A) and AA-stimulated (B) conditions in a stable HEK-293 cell line overexpressing Flag-PAT1. (C)
Under steady state conditions, immunoprecipitation of Flag-PAT1 leads to co-immunoprecipitation of endogenous RagC, but not tubulin. (D)
Conversely, immunoprecipitation of Flag-RagD, but not Flag-Rap2A, both transiently expressed in HEK-293 cells, leads to co-immunoprecipitation of
endogenous PAT1, but not tubulin, suggesting that the Rag GTPases complex with PAT1 in cells. Scale bar in A is 10 mm and applies to all panels in A
and B.
doi:10.1371/journal.pone.0036616.g003
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the PATs (Figures 5B and 5C compared to 5A; [49]). However,
one UAS-CG1139-GFP line (line 2) gave a bulged eye phenotype,
which is commonly observed when growth is strongly stimulated in
the differentiating eye (Figure 5F); c.f. [49,51].
We have previously shown that co-expression in the eye of
growth regulatory genes with the transcription factor FOXO,
provides a highly sensitive test for TORC1 signalling components
[49]. Increased TORC1 activity, which normally promotes
growth, suppresses PI3K/Akt signalling via a negative feedback
mechanism [52,53], and this appears to enhance the pro-apoptotic
effects of FOXO ([46,49]; Figures 5N and 5O compared to 5M).
All UAS-PAT-GFP lines strongly exacerbated the FOXO-induced
reduced eye phenotype (Figures 5P–R), even though they
generally produced a modest overgrowth phenotype when
expressed alone, indicating that the fusion proteins they produce
interact similarly to untagged PATs with the TORC1 signalling
cascade.
To test whether the UAS-PAT-GFP insertion lines give different
phenotypes, because they are expressed at different levels as a
result of the chromosomal position of each transgene insertion, we
expressed all of these lines in the late third instar larval fat body
using the Lsp2-GAL4 driver and measured transcript levels by Q-
RT-PCR (Methods S1 and Figure S1). Only the CG1139-GFP
line 2, which produces strong phenotypes, was expressed at levels
comparable to the UAS-PAT lines we have used in previous
studies (Figure 5 and Figure S1 [46]). Although confocal
fluorescence microscopy reveals detectable levels of CG1139-
GFP and PATH-GFP fusion proteins in the fat body for the other
PAT-GFP lines (see below), transcripts from these GFP-tagged
constructs are expressed at similar levels to endogenous PATs. We
conclude that PAT-GFP fusion proteins are functional in vivo and
that the weakest expressing lines, particularly CG1139-GFP line 1,
which is primarily employed in the analysis presented below,
provide powerful tools to assess PAT localisation without
producing a strong effect on TORC1 signalling.
Drosophila PATs, like mammalian PATs, are localised to
the cell surface and LEL membranes in multiple cell types
The PAT-GFP open reading frames (ORFs) were cloned into a
metallothionein-inducible vector to permit expression in Drosophila
Schneider 2 (S2) cells. Even in the absence of copper induction,
the fusion proteins were produced at detectable levels. However,
relatively few transfected cells with normal morphology were
observed with the CG1139-GFP construct, suggesting a toxic
effect when overexpressed in this system. We therefore focused our
analysis on PATH-GFP in this cell type. This fusion protein was
located mainly on intracellular organelles (e.g., Figures 6A and B),
with limited cell surface expression. Many, but not all, of the GFP-
positive intracellular organelles were also labelled with Lyso-
Tracker Red, which stains acidic lysosomes and at least some late
endosomes, in living cells. However, the majority of the largest
organelles that stained most strongly with Lysotracker Red, which
are likely to be lysosomes, were not GFP-positive. Based on the
proposed topology of PAT1 [54], the C-terminal GFP tag on the
PATH and CG1139 fusion proteins employed in this study would
be predicted to lie on the intralumenal face of the intracellular
compartments. It is therefore very likely that the GFP tag is
degraded or inactivated in lysosomes, explaining the absence of
GFP in these organelles in Drosophila when compared to
endogenous PAT proteins in mammalian cells.
To assess the localisation of PAT-GFP in living tissue, the fusion
constructs were expressed using the Lsp2-GAL4 driver [55] in the
larval fat body, which contains large cells that have previously
been used to study the subcellular localisation of AATs [22]. The
intracellular distribution of PATs in living cells with respect to
Lysotracker Red staining was comparable to S2 cells (e.g., PATH-
GFP in Figures 6C and D), although there was an increased level
of general cytoplasmic GFP staining observed and substantial
plasma membrane expression. GFP was localised at the surface
rather than in the lumen of the largest organelles (Figure 6D),
consistent with its membrane localisation.
To determine more precisely in which intracellular organelles
the fusion proteins reside, we co-stained larval fat bodies with
antibodies against proteins that mark specific subcellular com-
partments (Methods S1). Although there was only limited co-
localisation with markers for early endosomes, which are typically
localised to a perinuclear region in the fat body (e.g. see Figure S2
[56]), most of the GFP-positive organelles also expressed an HRP-
Lamp1 fusion protein (yellow arrows in Figure 6E) that is primarily
found on the surface of LELs [56]. We conclude that under
normal physiological conditions in living flies, the PATs reside at
the cell surface and on the membranes of LELs within fat body
cells, whereas in Schneider cells in culture, PATs are largely at the
surface of LELs.
Figure 4. PAT1 modulates the AA-dependent relocalisation of
mTOR to LELs. (A, B) Knockdown of PAT1 (PAT1 kd) in HEK-293 cells
reduces the AA-stimulated accumulation of mTOR (green) to LAMP2-
positive (red) LELs (B), when compared to cells treated with a scrambled
siRNA (scr; A). (C, D) Importantly, PAT1 knockdown does not eliminate
all PAT1 protein from cells (compare D with control cells in C), so
residual mTOR relocalisation in B may result from the presence of low
levels of PAT1. PAT1 antibody staining is shown in green, LAMP2 in red.
Scale bar in A is 10 mm and applies to all panels.
doi:10.1371/journal.pone.0036616.g004
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PATs and enhances their growth-promoting properties
Our previous analysis of cells mutant for a hypomorphic path
allele suggested that PATH plays a more important role in cell-
autonomous growth regulation in cells where signalling by Rheb, a
monomeric G protein that can act downstream of PI3K/Akt to
positively regulate TORC1 activity [57,58], is elevated [49]. To
further investigate this link, tagged and untagged PATs were co-
expressed using the GMR-GAL4 driver in the differentiating eye
with Rheb. The growth-promoting effects of the PATs, particu-
larly those that when expressed alone produced obvious
overgrowth phenotypes, were strongly enhanced in the presence
of Rheb (Figures 5H–L compared to 5B–F and 5G). However,
even the weakest PAT-GFP lines produced a more bulged and
disorganised eye.
Akt can indirectly activate Rheb by blocking the inhibitory
effects of the Tuberous sclerosis Complex (TSC; [59]). To test
whether upregulating PI3K/Akt signalling in the eye could also
modulate the growth-promoting activity of the PATs (Figures 7B
and C compared to 7A), we generated eyes that were almost
entirely mutant for the key antagonist of this pathway, the fly
homologue of the major tumour suppressor gene, PTEN
(Figure 7D; [17,60]), using the ey-FLP/FRT somatic recombina-
tion system and a recessive cell lethal chromosome [61]. There was
a strong synergistic interaction between PTEN and both the
CG1139 and path transporter genes. PTEN mutant eyes expressing
these molecules under GMR-GAL4 control were more bulged
compared to non-expressing eyes, and contained visibly larger and
more disorganised ommatidia (Figures 7E and 7F compared to
7B–D). Thus, PI3K/Akt/Rheb signalling synergises with overex-
pressed PATs to promote in vivo growth in the eye.
Hennig et al., 2006 previously showed that elevated Rheb
signalling in the fat body promotes bulk endocytosis, and provided
evidence that bulk and selective endocytic regulatory events act
both upstream and downstream of TORC1 signalling. We tested
whether the synergistic interaction between PI3K/Akt/Rheb and
the PATs might be linked to a change in the subcellular
localisation of the PATs. Co-expression of the PATs with Rheb
using Lsp2-GAL4 significantly increased the size of fat body cells
by 1.7660.24 fold relative to cells only expressing the PAT
(1.0060.14; P,0.001; Figures 8C and 8F), and altered the
subcellular distribution of the PATs, which accumulated at much
higher levels within cells, including a region around the nucleus
(compare Figure 8A to 8C). Fluorescence intensity measurements
specifically in this perinuclear region compared to the plasma
membrane revealed a highly significant approximately two-fold
increase in perinuclear GFP expression when Rheb is overex-
pressed with CG1139-GFP (Figures 8E and 8F). Since the HRP-
Lamp1 fusion protein is localised in structures positioned
throughout the cytoplasm both in the absence and presence of
Rheb (Figures S2C and S2D), this specific pool of perinuclear
CG1139 is probably not located in LELs. However, early
endosomes, marked by a UAS-GFP-FYVE transgene [62], are
found in a perinuclear region in this tissue [56] and GFP-FYVE-
positive structures are also perinuclear in Rheb-overexpressing fat
bodies (Figure S2B), suggesting that some of the PATs are most
likely endocytosed to early endosomes when Rheb is overex-
pressed, as well as to other structures that are not perinuclear,
which are likely to be LELs.
Figure 5. Drosophila PAT-GFP fusion proteins have similar functional activities to untagged PATs in vivo. Untagged transporters
synthesised from GS insertions in path (path
GS13857; B, H, N) and CG1139 (CG1139
GS10666; C, I, O), and tagged transporters synthesised from UAS-Path-
GFP (D, J, P) and UAS-CG1139-GFP line 1 (E, K, Q) and line 2 (F, L, R) insertions were expressed in the differentiating cells of the fly eye with GMR-GAL4
in the presence or absence of other transgenes. (A–F) Overexpression of path
GS13857 (B) and CG1139
GS10666 (C) produces a significant increase in
ommatidial size relative to controls (A). A more subtle, but also significant, increase in growth was seen for PATH-GFP (D) and CG1139-GFP line 1 (E).
CG1139 line 2 produced a bulging and disorganised eye phenotype (F). For size comparisons, n=6; bottom of panels A–E, mean 6 s.d. relative to
control; * P,0.05, ** P,0.01, ***P,0.001. (G–L) The overgrowth induced by overexpressing UAS-Rheb with GMR-GAL4 (G) is synergistically enhanced
by co-expression of tagged and untagged transporters (H–L), suggesting a role for Rheb signalling in controlling the growth-promoting activity of
PATs. (M–R) The apoptotic, reduced eye phenotype produced by overexpression of foxo
GS9928 with GMR-GAL4, which is most clearly seen at the
ventro-posterior edge of the eye (arrow in M), is enhanced by co-expression of tagged and untagged transporters (N–R), consistent with these
molecules acting through the TORC1 signalling cascade to inhibit Akt and enhance, FOXO activity. Scale bar is 100 mm and applies to all panels.
Ommatidial size measurements were made when expression of transgenes did not disturb the ommatidial array.
doi:10.1371/journal.pone.0036616.g005
PAT1 Regulates TORC1 on LELs
PLoS ONE | www.plosone.org 6 May 2012 | Volume 7 | Issue 5 | e36616To test whether Rheb-dependent endocytosis of CG1139 is
critical for the synergistic interaction between these molecules,
CG1139-GFP was co-expressed in the fat body both in the
absence and presence of Rheb with an inhibitory form of the
dynamin homologue Shibire, Shi
K44A [63], which blocks endocy-
tosis (Figures 8B and 8D respectively). Intracellular levels of
CG1139-GFP were significantly reduced in both cases to similar
levels (Figure 8F), showing that the accumulation of intracellular
PATs in fat body cells in the presence or absence of Rheb
overexpression requires endocytosis from the cell surface. Inter-
estingly, blocking Shibire function also completely and selectively
suppressed the cell size increase induced by Rheb and PAT co-
expression (Figure 8F), demonstrating that endocytosis is an
important contributor to the synergistic growth-promoting func-
tions of these two molecules in fat body cells.
To investigate whether Rheb’s effects on PAT subcellular
localisation are conserved in other cell types, we expressed
CG1139-GFP in the differentiating eye using the GMR-GAL4
driver in the absence or presence of Rheb. Co-expression of Rheb
and CG1139-GFP produced a large increase in adult ommatidial
size (Figure 5K compared to 5G and 5E) and in photoreceptor size
in the larval eye imaginal disc (compare Figures 8H to 8G). In the
absence of Rheb, CG1139 was highly expressed at the cell surface,
as evidenced by the ring of staining associated with the membranes
of non-photoreceptor cells around each ommatidial unit
(Figure 8G). This staining was less pronounced in eyes overex-
pressing Rheb, with each photoreceptor cell having more diffuse
non-nuclear intracellular GFP (Figure 8H). In addition, intense
punctae of intracellular staining were observed in these latter cells
(Figure 8H), consistent with our interpretation that PATs are
endocytosed in response to increased Rheb signalling. Overall we
conclude that PI3K/Akt/Rheb signalling enhances the growth-
promoting properties of the PATs and that this process requires
endocytosis. Since we have shown in mammalian cells that LEL-
located PATs are involved in mTORC1 activation, the synergistic
Figure 6. Drosophila PATs are localised at the cell surface and
on LEL compartments in vivo. (A, B) Expression of PATH-GFP (green)
in living Drosophila S2 cells stained with the acid-sensitive dye
Lysotracker Red. Some PATH-GFP is found at the plasma membrane
(white arrow), but most is at the surface of intracellular compartments.
It does not generally co-localise with the most intensely stained
Lysotracker Red-positive compartments (likely to be lysosomes, e.g. red
arrows), but does co-localise with the less intensely stained Lysotracker
Red-positive compartments (probably late endosomes and some
lysosomes, e.g. yellow arrows), perhaps because GFP fluorescence or
integrity is affected in highly acidic conditions. In addition, some PATH-
GFP-containing compartments do not co-stain with Lysotracker Red
(e.g. green arrows). (C, D) PATH-GFP (green) expressed under Lsp2-
GAL4 control in the larval fat body also co-localises with only a subset of
Lysotracker Red-positive compartments in living tissue (e.g. examples
marked with arrows as in A and B), but is also expressed at high levels at
the surface of cells. Note in D, PATH-GFP is specifically expressed at the
surface of some larger Lysotracker Red-positive structures (yellow
arrows) and other membrane structures (green arrows), consistent with
its known membrane-association. (E) CG1139-GFP co-localises with
many, but not all compartments stained with HRP-Lamp1, a late
endosomal and lysosomal marker, in fixed larval fat bodies (e.g. yellow
arrows), suggesting that some, but not all, intracellular CG1139 is in
LELs. Nuclei are stained with DAPI (blue) in E0. Scale bar is 5 mmi nA ,B
and D, and 20 mm in C and E.
doi:10.1371/journal.pone.0036616.g006
Figure 7. The growth-promoting activity of PAT transporters is
synergistically enhanced by hyperactivation of PI3K/Akt
signalling. (A–C) GAL4-UAS-induced overexpression of the fly PAT
transporter genes, path (B) and CG1139 (C) in the differentiating eye
with GMR-GAL4 promotes increased growth compared to normal
animals (A). (D–F) When overexpressed in a PTEN mutant background
(D), the effect of path (E) and CG1139 (F) on growth is synergistically
enhanced, resulting in a highly overgrown, bulging eye phenotype.
Ommatidial size measurements are given for eyes where the
ommatidial array is regularly arranged (n=6; bottom of panels A–C,
mean 6 s.d. relative to control (A); *P,0.001, increased relative to
control). Fly genotypes are w; GMR-GAL4 (A), w; GMR-GAL4/path
GS13857
(B), w; GMR-GAL4/CG1139
GS10666 (C), yw ; PTEN
1 FRT40A/P[w
+]l(2)3.1 FRT
40A; GMR-GAL4 (D), yw ; PTEN
1 FRT40A/P[w
+]l(2)3.1 FRT 40A; GMR-GAL4/
path
GS13857 (E) and yw ; PTEN
1 FRT40A/P[w
+]l(2)3.1 FRT 40A; GMR-GAL4/
CG1139
GS10666 (F).
doi:10.1371/journal.pone.0036616.g007
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ling and PATs are presumably at least partly explained by
increased accumulation of PATs in LELs.
Discussion
The two ubiquitously expressed proton-assisted AATs, PAT1
and PAT4, have previously each been shown to act as essential
mediators of AA-dependent mTORC1 activation in rapidly
growing HEK-293 cells, even though at least one of these
molecules, PAT1, is almost exclusively intracellular [46]. In this
paper, we demonstrate that in these cells intracellular PAT1 is
primarily located in LELs and that it forms a complex with the
Rag GTPases, molecules that are also involved in AA-dependent
mTORC1 activation. Our data suggest that this PAT1/Rag/
Ragulator complex plays a key role in the process of AA-sensing
that regulates Rag-dependent mTOR relocalisation to the LELs,
and activates mTORC1 signalling. Although PAT4 is also
required for AA-stimulated TORC1 activation [46], we have
not yet been able to determine whether it is also part of this
complex. Importantly, PATs are found at both the cell surface and
LELs in living flies. Altering PI3K/Akt1/Rheb signalling in vivo
promotes endocytosis of PATs, a process required to produce
synergistic growth regulatory interactions between these mole-
cules. These findings partly explain how signals from growth
factors, extracellular nutrients and LELs might interact together to
maximise mTORC1 activation [26].
PAT1 complexes with Rag GTPases and mediates amino
acid-dependent mTORC1 activation from LEL
compartments
The data presented in this study highlight a critical role for
PATs on the surface of LELs in regulation of TORC1/S6K
Figure 8. PI3K/Akt/Rheb signalling promotes shuttling of the PATs to endosomal compartments. (A, C) CG1139-GFP expressed in the larval
fat body using Lsp2-GAL4 is localised to both the plasma membrane (white arrow) and also to intracellular LELs throughout the cytoplasm (yellow arrow;
A). Overexpression of Rheb leads to an increase in the relative proportion of intracellular, including perinuclear, protein compared to cell surface CG1139-
GFP (C). (B, D) When CG1139-GFP is co-expressed with a dominant negative version of Shibire, Shi
K44A, which blocks endocytosis, in either the presence
(D) or absence (B) of Rheb, the transporter is mostly located at the plasma membrane (white arrow), strongly suggesting that PATs are normally shuttled
toLELsfromthecellsurface.(E,F)TheratiooftheGFPsignalintensityina2.25 mmperinuclearregionanda2.25 mmregionat theplasmamembrane(see
E) was measured for genotypes in A–D (grey bars; error bars=s.d. in F). Average cell size for each genotype is also shown in F (blue bars; error bars=s.d.).
n=25; *P,0.001 (increased) and & P,0.001 (decreased) relative to non-Rheb/non-Shi
K44A-expressing control; &&P,0.001, decreased relative to Rheb-
overexpressing control. Rheb-induced changes in intracellular PATs and PAT-induced growth are entirely dependent on endocytosis. (G, H)I nt h el a r v a l
eye imaginal disc, CG1139-GFP, expressed under GMR-GAL4 control (G), is mostly located at or near the plasma membrane, for example at the surfaces of
flattened non-photoreceptor cells that surround each ommatidium (white arrows). Co-overexpression of Rheb (H) results in much larger ommatidia, with
reduced staining around the ommatidial border (white arrow) and more CG1139-GFP cytoplasmic expression, including intense intracellular punctae of
staining (yellow arrows), consistent with Rheb promoting endocytosis of PATs in this tissue. An outline of an individual ommatidium in G and H is marked
with a dashed line. Scale bar in A is 20 mm and applies to panels A–D, scale bar in G is 5 mm and applies to panels G and H.
doi:10.1371/journal.pone.0036616.g008
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located at the cell surface and/or the surface of LELs and that
their distribution is cell type-specific [64–67]. In rapidly growing
cells, such as HeLa cells [48], MCF7 and HEK-293 cells [46],
PAT1 is almost exclusively localised on intracellular membrane-
bound structures, which we now demonstrate for HEK-293 cells
are LAMP2-positive LELs. In the fly fat body, GFP-tagged
versions of CG1139 and PATH, two fly growth-regulatory PATs,
partially co-localise with LEL markers. In contrast to rapidly
proliferating Drosophila S2 cells in culture, a significant proportion
of these transporter proteins are also located at the plasma
membrane, where these proteins presumably cannot modulate
TORC1 activity via the LEL-dependent mechanism observed in
mammalian cell culture.
PATs are, to date, the only intracellular molecules implicated in
AA-dependent mTOR activation that are known to bind to AAs.
Our findings that PAT1 is located in LELs, some of which recruit
mTOR upon AA stimulation, and that PAT1 co-immunoprecip-
itates with Rag GTPases, other key molecules that play an
evolutionarily conserved role in this process [28–30] strongly
suggest that the PAT1/Rag/Ragulator complex functions in some
form of AA-sensing mechanism operating in specific LELs that is
critical for mTORC1 activation (Figure 9).
Indeed, the close proximity of membrane-associated immuno-
reactive mTOR and PAT1 molecules in our EM studies and the
effect of PAT1 knock down on AA-dependent mTOR relocalisa-
tion are consistent with a model in which this PAT1/Rag complex
can recruit mTOR directly. Although the PAT1 knock down
experiments did not completely block mTOR relocalisation
(compare Figures 4A and 4B), we found that this approach did
not completely remove all PAT1 mRNA and protein (compare
Figures 4C and 4D; [46]), and so it is possible that low levels of
PAT1 can still recruit some mTOR to LELs, but cannot activate it
normally. Alternatively, there may be other AA-binding molecules
that can partially substitute for PAT1 in this process or that play
an important role in initially recruiting mTOR to the LELs.
Regulation of PAT trafficking and its role in growth
regulation
To study the subcellular localisation of the PATs in vivo,w e
employed GFP-tagged forms of PATH and CG1139 that are
functionally active, but expressed at low levels, to minimise their
effect on the TORC1 signalling cascade, which is known to
stimulate endocytosis in flies [22]. Indeed, most of the CG1139-
GFP fusion protein produced by the strongly expressing line 2
(Figure 5) is predominantly found in endosomes and lysosomes,
even under normal Rheb signalling conditions (data not shown),
consistent with the idea that when highly expressed, these
molecules can self-regulate their subcellular localisation via
TORC1. Co-expression of these tagged PATs in the fat body
with dominant negative Shibire, which blocks endocytosis, leads to
accumulation of these molecules at the cell surface, eliminating the
possibility that these fusion proteins are abnormally trapped
during synthesis and processing in the ER or Golgi, or
inappropriately by pass the plasma membrane on their way to
LELs.
In this in vivo system, elevated PI3K/Akt/Rheb signalling not
only promotes PAT-mediated growth synergistically, but increases
the proportion of perinuclear to plasma membrane PATs,
consistent with the idea that intracellular PATs are critical for
growth control. None of our data exclude the existence of
TORC1-regulatory mechanisms involving other subcellular com-
partments. Nor do they exclude the possibility that other
mechanisms could link PI3K/Akt with mTORC1 signalling at
LELs (e.g., Rheb interaction with TORC1 [30] or the regulation
of pH in LELs [68]). But collectively our data do indicate that
PATs and growth-regulatory TORC1 signalling from LELs
become critically important as PI3K/Akt/Rheb signalling is
increased. Indeed, although blocking endocytosis only slightly
inhibits normal growth of the fat body, it completely suppresses
Rheb-induced overgrowth (Figure 8). Hennig and co-workers have
previously presented evidence that endocytosis modulates TORC1
signalling in flies, having both positive and negative effects in
different developmental scenarios [22]. Our data are consistent
with their idea that this function may be linked to shuttling of
different nutrient transporters. Indeed, our studies suggest that the
critical AATs involved in TORC1 activation may change as
PI3K/Akt/Rheb signalling is elevated, with PATs playing an
increasingly important role, hence explaining how endocytosis can
modulate TORC1 in a context-dependent fashion.
As already discussed above, PATs may function in the
mTORC1 activation process by sensing intralumenal AAs in
LELs. This might be particularly important when the PI3K/Akt/
Rheb pathway is hyperactivated, as in cancer, since cells could
shield themselves from changes in extracellular AA levels by
increasing their dependence on AA-dependent PAT signalling in
LELs, providing a partial explanation for the known growth
advantage of these cells, even in starvation conditions [24].
It has recently been demonstrated that during autophagy,
cultured human cells employ AAs in the lumen of the autolyso-
some to activate mTORC1 and promote survival [42]. The
process of autophagy is also critical for the survival of cancer cells
exposed to stresses such as hypoxia [69,70]. It will now be
interesting to investigate whether PATs are involved in these
processes. If they are, PATs may represent novel and selective
drug targets for inhibiting growth of cancer cells under these
conditions.
A new model for mTORC1 regulation in LELs via the PAT-
containing nutrisome complex
Since PATs are proton-dependent amino acid transporters that
can potentially export AAs out of LELs, the simplest explanation
for their mTORC1 regulatory activity is that PAT-dependent,
proton-mediated AA transport out of the LELs is required to
activate mTORC1 signalling at the LEL membrane. A recent
report has identified the vacuolar H
+-ATPase (v-ATPase) as an
additional component of the Rag/Ragulator complex that senses
intralumenal AAs. These AAs rapidly accumulate inside LELs in
response to addition of extracellular AAs, and then recruit and
activate mTORC1 on LELs [41]. Perhaps, the most straightfor-
ward explanation of these and our data is that PATs and the v-
ATPase function as an AA-sensing engine (or ‘nutrisome’) at the
LEL membrane (Figure 9). PATs transport AAs and protons out of
the LELs, and the coupled v-ATPase pumps the protons back into
the LEL lumen. Zoncu et al. (2011) have already established that
the v-ATPase undergoes altered interactions with the Rag/
Ragulator complex in response to AAs. It, therefore, seems likely
that AA-driven nutrisome activity induces conformational changes
in either this molecule, or the PATs or both, that relay a signal to
the Rag GTPases to regulate mTORC1 activity.
Although studies in vivo and in cell culture [46,49] have shown
unequivocally that PATs drive growth and mTORC1 activation,
high level overexpression can inhibit these processes in the same
systems [41,49]. Since much of the overexpressed PAT protein is
unlikely to be coupled to Rag GTPases and merely drains the LEL
lumen of specific AAs that are substrates for PATs, these data are
consistent with a model where the PAT/Rag/Ragulator-v-
ATPase complex is required to establish a microenvironment for
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AA-sensing nutrisome. The coupling of v-ATPase and PATs may
also explain why reducing the proton gradient, though not the
electrochemical potential, across the LEL membrane by treatment
with the ionophore FCCP does not block AA-dependent mTOR
relocalisation [41].
This model provides a first mechanistic explanation of how
mTORC1 senses AAs and a useful framework for more detailed
analysis of the AA-sensing mechanisms involved. For example, it
will now be important to test the importance of PAT transporter
activity in mTORC1 activation, since PATs may also be able to
signal to downstream targets via a proton-stimulated transceptor
mechanism [16]. Furthermore, the fact that human PAT4 and one
of the fly PAT transporters, PATH, which both promote
mTORC1-dependent growth, are low capacity, proton-indepen-
dent, high affinity transporters [49,71], suggests that these
Figure 9. AA-dependent regulation of mTORC1in late endosomes and lysosomes via the PAT1/Rag/Ragulator/v-ATPase nutrisome
complex. We have shown that Proton-assisted Amino acid Transporters (PATs) localised on late endosomes and lysosomes (LELs) interact with Rag
GTPases (Rags) and are required for mTORC1 activation. The Ragulator is a trimeric group of proteins involved in attaching the complex to the lipid
bilayer. Recent studies [41] have also demonstrated that the vacuolar H
+-ATPase (v-ATPase) interacts with the activated Rag (Rag*)/Ragulator
complex to control amino acid (AA)-dependent mTORC1 activation and that this is regulated by the rapid accumulation of extracellular AAs in LELs.
This suggests a model where, in response to AAs (compare upper LEL to lower AA-stimulated LEL), these different molecules form a complex that we
call the ‘nutrisome’. Cycling of protons through this nutrisomal engine induces conformational changes that activate mTORC1, leading to increased
translation and cell growth. Importantly, signalling from the insulin receptor (InR) and subsequent activation of the PI3K/Akt/Rheb cascade promotes
shuttling of PATs from the cell surface to LEL membranes, hence increasing PAT-dependent mTORC1 activation and cell growth. In addition, the
accumulation of AAs in the LEL lumen presumably involves transport into intracellular endosomal compartments (depicted by compartment on left
hand side) via currently unknown amino acid transporters (AATs) or potentially endocytosis. Cytoplasmic leucine (Leu), which may be brought into
cells via the heterodimeric AAT, CD98 [34], has been shown to play a key role in activating mTORC1 in some cultured cells and may play a key role in
this process. Influx of Leu or other AAs into the endolysosomal system may ultimately allow the AA substrates of PAT1 to accumulate in the LELs
through AA exchange mechanisms, leading to PAT1-mediated activation of the nutrisome. Interactions leading to activation or inhibition of
downstream components are depicted by solid arrows and solid bars respectively, movement of specific molecules by dashed arrows and processes
involving membrane shuttling by dotted arrows.
doi:10.1371/journal.pone.0036616.g009
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is also of interest that the mechanisms that target AAs to the LELs
are completely unknown. Such mechanisms might involve AAs
like leucine, which is not a substrate for PAT1, but appears to play
an important role in AA-dependent mTORC1 activation, since it
could be important for AA exchange processes that target other
AAs to LELs. Whatever subsequent studies reveal, the data
presented here highlight the LELs and PAT transporters as critical
players in AA sensing and potentially important new targets in
specifically inhibiting cancer cell growth.
Materials and Methods
Culture of human cells
HEK-293 cells (ATCC), were cultured in MEM (Minimum
Essential Medium Eagle; Sigma-Aldrich) supplemented with 10%
fetal bovine serum (Gibco Invitrogen, Paisley, UK), 16NEAA
(Sigma-Aldrich, Poole, UK) and 4 mM L-Glutamine (Gibco
Invitrogen), in the presence of 1% Penicillin/Streptomycin
(Invitrogen) at 37uC, 5% CO2. Cells were either maintained in
this medium (steady state conditions) or AA-starved and in some
cases AA-stimulated for 10 min as described in [46], except that
4 mM glutamine was added to the AA stimulation medium.
Generation of stable HEK-293 cell lines
Stable cell lines carrying either a pcDNA3.1(+) (Invitrogen)
construct containing Flag-PAT1 or the empty pcDNA3.1(+) vector
were generated as described in [46].
Drosophila S2 cell culture
For immunostaining, Drosophila S2 cells were transfected with
pMT/V5-HisB-path-EGFP using FuGENE HD (Roche, Welwyn
Garden City, UK; 3 ml FuGENE to 1 mg DNA) in the presence of
100 mM CuSO4 and stained four days later (see below).
PAT1 knockdown experiments
PAT1 was knocked down in HEK-293 cells using MaTra
transfection as described in [46]. Two different siRNAs (si158,
si159) were used in different experiments and produced similar
results. Cells were analysed by immunostaining 72 h after
transfection according to method outlined in [30].
Immunostaining
The following primary antibodies: mouse anti-Flag; (1:200;
Abcam, ab18230), rabbit anti-mTOR (7C10; 1:200; Cell Signal-
ing Technology, CST), rabbit anti-RagC (1:100; CST), rabbit
anti-PAT1 (1:1,000; [48]), rat anti-LAMP2 (1:100; Abcam
ab13524) and mouse anti-LAMP2 (1:100; Abcam ab25631) and
secondary antibodies raised in donkey (1:500; Jackson ImmunoR-
esearch) were used. Cells were stained according to the procedure
described in [30]. Samples were then mounted in Vectashield with
DAPI (0.1 mg/ml; Vector Laboratories) and imaged on a Zeiss 510
confocal microscope. Fat body sample preparation for confocal
analysis is described in Supplemental data (Methods S1).
Co-immunoprecipitation
HEK-293 cells were transiently transfected one day after plating
in 6-well plates using MATra transfection, as described in [46]
with Addgene plasmid 19316 (Flag pLJM1 RagD) or Addgene
plasmid 19311 (Flag pLJM1 Rap2A) and incubated for two days
prior to lysis. Stable HEK-293 cell lines containing either the Flag-
PAT1 construct or the empty pcDNA3.1(+) vector were plated two
days before lysis in 6-well plates. Cells were lysed with ice-cold
RIPA buffer containing a protease inhibitor cocktail (1:100;
Sigma-Aldrich) for 30 min at 4uC with gentle rocking. Cell lysates
cleared by centrifugation (10 min at 42,000 g; (Beckman J2-HS
Centrifuge) at 4uC were processed with the FlagIPT-1 kit (Sigma-
Aldrich) according to the manufacturer’s instructions and then
analysed alongside input controls by SDS-PAGE.
Drosophila strains, crosses and phenotypic analysis
The following fly strains were used: UAS-shi
K44A [63], UAS-
HRP-Lamp1 [56], UAS-GFP-FYVE [62], PTEN
1 [60], UAS-Rheb
[57], GMR-GAL4, Lsp2-GAL4, arm-GAL4 (Bloomington Stock
Center) and the GS lines [72] path
GS13857, CG1139
GS10666 and
foxo
GS9928 (gifts from Toshiro Aigaki). Other fly stocks, genetic
crosses and the method for ommatidial size measurement were as
described in [49]. Flies were cultured on standard cornmeal agar
food at 25uC.
Western blotting
Crude RIPA lysates from human cells were cleared by
centrifugation (13,000 rpm; 10 min; 4uC). In this case, sample
concentration was determined using Bradford protein quantifica-
tion (BioRad) and about 40 mg of boiled protein were routinely
loaded onto a 10% SDS polyacrylamide gel and transferred to
nitrocellulose membrane (Whatman). Membranes were blocked in
TBS+0.1% Tween ([v/v]; TBST)+5% BSA or non-fat dry milk for
1 h, and washed 365 min in TBST before overnight incubation in
primary antibody. The following primary antibodies were used:
anti rabbit anti-RagC (1:1,000; CST) in 5% BSA, mouse anti Flag
M2 (1:500; Sigma Aldrich) in 3% non-fat dry milk, rabbit anti-
Flag (1:1000; CST) in 5% BSA, rabbit anti-PAT1 (1:10,000; [48])
in 5% non-fat dry milk and mouse anti-a-tubulin (1:10,000;
Sigma-Aldrich) in 5% non-fat dry milk. Membranes were washed
365 min, incubated for 1 h in HRP-conjugated secondary
antibodies (1:4,000; Jackson ImmunoResearch) and washed
365 min in TBST before ECL detection (Amersham).
Lysotracker staining
For lysotracker staining, fat bodies of late third instar larvae
were dissected in Schneider’s medium (Gibco), incubated for
2 min in 10 mM LysoTracker Red DND-99 (Molecular Probes) in
PBS, mounted in Schneider’s medium on glass slides and imaged
immediately. For lysotracker staining in S2 cells, medium was
replaced with fresh medium (pre-warmed) containing 100 nM
Lysotracker Red DND-99, mounted directly on glass slides and
imaged within 5 min on a Zeiss 510 confocal microscope.
Analysis of CG1139-GFP subcellular localisation and cell
size measurements within fat body cells
Fat bodies from the anterior ends of third instar larvae were
dissected in 4% paraformaldehyde in PBS and incubated for
20 min at 4uC before washing for 365 min in PBST (PBS+0.3%
[v/v] Triton X-100) and staining by standard methods. They were
mounted using VectaShield containing DAPI (Vector Laborato-
ries). To determine the subcellular distribution of CG1139-GFP
and cell size, five fat bodies were analysed per genotype and five
random cells were imaged at the same magnification from each fat
body on a Zeiss 510 confocal microscope. For CG1139-GFP
localisation measurements, a horizontal line was drawn through
the middle of each cell and a pixel value profile plotted using
ImageJ. This was done for both CG1139-GFP (488 nm) and
DAPI (405 nm) to locate the nucleus on the CG1139-GFP plot.
The area under the pixel value curve for CG1139-GFP was
calculated for the two 2.25 mm regions just outside the nuclear
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membrane (see Figure 5E). Using these values, the ratio of
perinuclear versus plasma membrane signal intensity was calcu-
lated. For cell size measurements, each cell was outlined using
ImageJ. The average area value was then normalised against
CG1139-GFP-expressing control cells. Significance values were
calculated using a Student’s unpaired two-tailed t-test.
Supporting Information
Figure S1 PAT-GFP insertions are expressed at differ-
ent levels in vivo. Different UAS-PAT-GFP insertion lines and
the two Gene Search insertion lines [72] CG1139
GS10666 and
path
GS13857, were expressed using the Lsp2-GAL4 driver [50,55],
which produces detectable fusion protein in the fat body with all
PAT-GFP lines tested (e.g., Figure 6). Levels of CG1139 (A) and
path (B) transcripts in fat body RNA preparations were measured
using Q-RT-PCR and normalised relative to the levels of the
RpL32 housekeeping control transcript. These data revealed a
correlation between levels of PAT expression and the growth-
promoting activity of specific constructs. The CG1139-GFP line 2
insertion, which gives strong overgrowth and FOXO-dependent
cell death phenotypes (Figures 5F, L and R), produced comparable
transcript levels to CG1139
GS10666, which we have previously
employed to overexpress this transporter at high levels (Figure 5C;
[49]). path transcripts are normally expressed at moderate levels in
the fat body [73]. Levels of path transcripts increased when path-
GFP was expressed using the Lsp2-GAL4 driver, but only to about
half the level produced by path
GS13857, which gives stronger
phenotypes when overexpressed in the eye (Figures 5B, H and N).
*( P ,0.001) indicates significantly higher levels than Lsp2.con-
trol. & (P,0.001) indicates significantly lower levels of the fusion
transcript than with Lsp2.path
GS1385.
(TIF)
Figure S2 Expression pattern of endosomal markers in
the Drosophila larval fat body. (A–D) Figure shows
expression of the FYVE-GFP (early endosomal; A, B) and HRP-
Lamp1 (late endosomal; C, D) markers in the larval fat body. In
the presence (B, D) and absence (A, C) of Rheb, FYVE-GFP
(green) is largely confined to a perinuclear region (arrows), while
HRP-Lamp1 (red) has a more widespread punctate distribution
throughout the cytoplasm. Nuclei are stained with DAPI (blue).
Scale bar in A also applies to B and scale bar in C also applies to
D; both are 20 mm.
(TIF)
Methods S1 Subcloning, production of transgenic fly
lines, measurement of mRNA levels in Drosophila fat
bodies, fat body immunostaining.
(DOC)
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